United States was the largest of Regeneron Pharmaceuticals, Inc.’s 2 reported lines in fiscal 2024, at $11.94B — 77% of $15.60B.
| Geography | FY 2016 | FY 2018 | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| United States | $23.24B | $11.77B | $11.94B | ||
| Non-Us | — | $870.80M | $3.67B | ||
| Outside United States | $2.71B | — | — | ||
| Total | $25.95B | $12.64B | $15.60B |
In fiscal 2024, which ended December 31, 2024, the 2 regions Regeneron Pharmaceuticals, Inc. reported in this breakdown added up to $15.60B. That was up 23.4% from $12.64B in fiscal 2023. United States was the largest region, at $11.94B or 76.5% of the total, followed by Non-Us ($3.67B, 23.5%).
Compared with fiscal 2023, Non-Us grew the fastest, rising 320.9% to $3.67B.
Non-Us was first reported as a separate region in fiscal 2023. The table also keeps 1 region that Regeneron Pharmaceuticals, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers 5 fiscal years between 2016 and 2024, as reported in Regeneron Pharmaceuticals, Inc.'s annual filings.
As Previously Reported was the largest of Regeneron Pharmaceuticals, Inc.’s 2 reported lines in fiscal 2018, at $15.64B — 126% of $12.43B.
| Restatement | FY 2018 |
|---|---|
| As Previously Reported | $15.64B |
| Adjustments | -$3.21B |
| Total | $12.43B |
In fiscal 2018, which ended December 31, 2018, the 2 revenue lines Regeneron Pharmaceuticals, Inc. reported in this breakdown added up to $12.43B. As Previously Reported was the largest revenue line, at $15.64B or 125.8% of the total.
Figures are shown as reported, so the total is net of Adjustments, which was -$3.21B in fiscal 2018. This breakdown covers every fiscal year from 2018 to 2018, as reported in Regeneron Pharmaceuticals, Inc.'s annual filings.
Collaboration Revenue was the largest of Regeneron Pharmaceuticals, Inc.’s 5 reported lines in fiscal 2021, at $6.15B — 88% of $6.99B.
| Income Statement Location | FY 2021 |
|---|---|
| Collaboration Revenue | $6.15B |
| Sga Expense | $568.40M |
| (Rd Expense)/Reduction Of Rd Expense | $10.40M |
| Cost Of Goods Sold | $253.20M |
| Other Operating Income | $12.20M |
| Total | $6.99B |
In fiscal 2021, which ended December 31, 2021, the 5 revenue lines Regeneron Pharmaceuticals, Inc. reported in this breakdown added up to $6.99B. Collaboration Revenue was the largest revenue line, at $6.15B or 87.9% of the total, followed by Sga Expense ($568.40M, 8.1%) and Cost Of Goods Sold ($253.20M, 3.6%). Together, the two largest revenue lines made up 96.1% of this total.
This breakdown covers every fiscal year from 2021 to 2021, as reported in Regeneron Pharmaceuticals, Inc.'s annual filings.
Regeneron Pharmaceuticals, Inc. (REGN) breaks its revenue down by region and revenue line. In fiscal 2024, its largest region was United States, with $11.94B or 76.5% of the total, followed by Non-Us at $3.67B (23.5%).
United States was Regeneron Pharmaceuticals, Inc.'s largest region in fiscal 2024, with $11.94B in revenue, 76.5% of the $15.60B reported across its 2 regions.
As Previously Reported was Regeneron Pharmaceuticals, Inc.'s largest revenue line in fiscal 2018, with $15.64B in revenue, 125.8% of the $12.43B reported across its 2 revenue lines.
Of the Regeneron Pharmaceuticals, Inc. regions reported in both fiscal 2023 and fiscal 2024, and making up at least 2% of the total, Non-Us grew the fastest, rising 320.9% from $870.80M to $3.67B.
Every figure is taken from Regeneron Pharmaceuticals, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2016 to 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.